TY - JOUR
T1 - Glucose metabolism alterations in patients with bipolar disorder
AU - Rosso, Gianluca
AU - Cattaneo, Annamaria
AU - Zanardini, Roberta
AU - Gennarelli, Massimo
AU - Maina, Giuseppe
AU - Bocchio-Chiavetto, Luisella
PY - 2015/6/29
Y1 - 2015/6/29
N2 - Patients with bipolar disorder (BD) are more frequently affected by metabolic syndrome (MetS) than the general population, but the neurobiological correlates underlying such association are still not clarified and few studies in BD have evaluated the role of regulators of lipid and glucose metabolism. The present study was aimed to investigate putative alterations in markers linked to metabolic dysfunctions as C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, Leptin, PAI-1 (total), Resistin and Visfatin in a sample of BD patients compared to controls. Furthermore, associations between changes of metabolic markers and relevant clinical features, such as severity of symptomatology, number and type of past mood episodes, drug treatments and presence/absence of metabolic alterations (MetS, diabetes and cardiovascular disease) were analyzed. A total of 57 patients with BD and 49 healthy controls were recruited. The main results showed lower serum levels of Glucagon, GLP-1, Ghrelin, and higher levels of GIP in BD patients as compared to controls (p=0.018 for Ghrelin; p
AB - Patients with bipolar disorder (BD) are more frequently affected by metabolic syndrome (MetS) than the general population, but the neurobiological correlates underlying such association are still not clarified and few studies in BD have evaluated the role of regulators of lipid and glucose metabolism. The present study was aimed to investigate putative alterations in markers linked to metabolic dysfunctions as C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, Leptin, PAI-1 (total), Resistin and Visfatin in a sample of BD patients compared to controls. Furthermore, associations between changes of metabolic markers and relevant clinical features, such as severity of symptomatology, number and type of past mood episodes, drug treatments and presence/absence of metabolic alterations (MetS, diabetes and cardiovascular disease) were analyzed. A total of 57 patients with BD and 49 healthy controls were recruited. The main results showed lower serum levels of Glucagon, GLP-1, Ghrelin, and higher levels of GIP in BD patients as compared to controls (p=0.018 for Ghrelin; p
KW - Bipolar disorder
KW - Ghrelin
KW - Glucagon
KW - Incretins
KW - Metabolic syndrome
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=84933507654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933507654&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2015.06.006
DO - 10.1016/j.jad.2015.06.006
M3 - Article
C2 - 26120808
AN - SCOPUS:84933507654
VL - 184
SP - 293
EP - 298
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
SN - 0165-0327
ER -